| Category | Name | IntersectionWithQuery | PValue | GenesInTerm | GenesInQuery | GenesInTermInQuery | ID |
|---|---|---|---|---|---|---|---|
| GeneOntologyMolecularFunction | type I interferon receptor binding | 8.85e-16 | 17 | 78 | 8 | GO:0005132 | |
| GeneOntologyMolecularFunction | cytokine activity | 5.94e-06 | 250 | 78 | 8 | GO:0005125 | |
| GeneOntologyMolecularFunction | cytokine receptor binding | 3.85e-05 | 324 | 78 | 8 | GO:0005126 | |
| GeneOntologyBiologicalProcess | positive regulation of peptidyl-serine phosphorylation of STAT protein | 5.65e-15 | 21 | 78 | 8 | GO:0033141 | |
| GeneOntologyBiologicalProcess | regulation of peptidyl-serine phosphorylation of STAT protein | 2.03e-14 | 24 | 78 | 8 | GO:0033139 | |
| GeneOntologyBiologicalProcess | serine phosphorylation of STAT protein | 8.46e-14 | 28 | 78 | 8 | GO:0042501 | |
| GeneOntologyBiologicalProcess | B cell proliferation | CD38 TLR4 GPR183 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 1.31e-12 | 124 | 78 | 11 | GO:0042100 |
| GeneOntologyBiologicalProcess | natural killer cell activation involved in immune response | 3.08e-12 | 42 | 78 | 8 | GO:0002323 | |
| GeneOntologyBiologicalProcess | response to exogenous dsRNA | 3.05e-11 | 55 | 78 | 8 | GO:0043330 | |
| GeneOntologyBiologicalProcess | response to dsRNA | 9.48e-11 | 63 | 78 | 8 | GO:0043331 | |
| GeneOntologyBiologicalProcess | interferon-mediated signaling pathway | 3.95e-10 | 112 | 78 | 9 | GO:0140888 | |
| GeneOntologyBiologicalProcess | regulation of receptor signaling pathway via JAK-STAT | 1.06e-09 | 125 | 78 | 9 | GO:0046425 | |
| GeneOntologyBiologicalProcess | type I interferon-mediated signaling pathway | 1.10e-09 | 85 | 78 | 8 | GO:0060337 | |
| GeneOntologyBiologicalProcess | cellular response to type I interferon | 1.21e-09 | 86 | 78 | 8 | GO:0071357 | |
| GeneOntologyBiologicalProcess | cellular response to virus | 1.75e-09 | 90 | 78 | 8 | GO:0098586 | |
| GeneOntologyBiologicalProcess | response to type I interferon | 2.09e-09 | 92 | 78 | 8 | GO:0034340 | |
| GeneOntologyBiologicalProcess | regulation of receptor signaling pathway via STAT | 3.49e-09 | 143 | 78 | 9 | GO:1904892 | |
| GeneOntologyBiologicalProcess | regulation of defense response to virus by host | 3.92e-09 | 63 | 78 | 7 | GO:0050691 | |
| GeneOntologyBiologicalProcess | positive regulation of peptidyl-serine phosphorylation | 4.41e-09 | 101 | 78 | 8 | GO:0033138 | |
| GeneOntologyBiologicalProcess | T cell activation involved in immune response | 4.72e-09 | 148 | 78 | 9 | GO:0002286 | |
| GeneOntologyBiologicalProcess | natural killer cell activation | 2.24e-08 | 124 | 78 | 8 | GO:0030101 | |
| GeneOntologyBiologicalProcess | lymphocyte proliferation | CD38 TLR4 GPR183 ITGAX IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 3.11e-08 | 398 | 78 | 12 | GO:0046651 |
| GeneOntologyBiologicalProcess | lymphocyte activation involved in immune response | TLR4 GPR183 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 3.63e-08 | 251 | 78 | 10 | GO:0002285 |
| GeneOntologyBiologicalProcess | mononuclear cell proliferation | CD38 TLR4 GPR183 ITGAX IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 3.87e-08 | 406 | 78 | 12 | GO:0032943 |
| GeneOntologyBiologicalProcess | regulation of defense response to virus | 4.88e-08 | 90 | 78 | 7 | GO:0050688 | |
| GeneOntologyBiologicalProcess | regulation of peptidyl-serine phosphorylation | 4.89e-08 | 137 | 78 | 8 | GO:0033135 | |
| GeneOntologyBiologicalProcess | cell surface receptor signaling pathway via JAK-STAT | 5.94e-08 | 198 | 78 | 9 | GO:0007259 | |
| GeneOntologyBiologicalProcess | B cell activation | CD38 TLR4 GPR183 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 6.22e-08 | 341 | 78 | 11 | GO:0042113 |
| GeneOntologyBiologicalProcess | B cell differentiation | 6.76e-08 | 201 | 78 | 9 | GO:0030183 | |
| GeneOntologyBiologicalProcess | leukocyte proliferation | CD38 TLR4 GPR183 ITGAX IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 1.05e-07 | 445 | 78 | 12 | GO:0070661 |
| GeneOntologyBiologicalProcess | cell surface receptor signaling pathway via STAT | 1.25e-07 | 216 | 78 | 9 | GO:0097696 | |
| GeneOntologyBiologicalProcess | defense response to virus | ITGAX IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 EPG5 | 6.38e-07 | 342 | 78 | 10 | GO:0051607 |
| GeneOntologyBiologicalProcess | leukocyte activation involved in immune response | TLR4 GPR183 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 1.04e-06 | 361 | 78 | 10 | GO:0002366 |
| GeneOntologyBiologicalProcess | cell activation involved in immune response | TLR4 GPR183 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 1.15e-06 | 365 | 78 | 10 | GO:0002263 |
| GeneOntologyBiologicalProcess | defense response to bacterium | RASGRP4 CD36 TLR4 IFNA4 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 2.92e-06 | 405 | 78 | 10 | GO:0042742 |
| GeneOntologyBiologicalProcess | humoral immune response | 3.40e-06 | 321 | 78 | 9 | GO:0006959 | |
| GeneOntologyBiologicalProcess | response to virus | ITGAX IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 EPG5 | 4.48e-06 | 425 | 78 | 10 | GO:0009615 |
| GeneOntologyBiologicalProcess | regulation of response to biotic stimulus | RASGRP4 CD36 TLR4 N4BP1 IFNA4 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 EPG5 | 5.04e-06 | 643 | 78 | 12 | GO:0002831 |
| GeneOntologyBiologicalProcess | response to organic cyclic compound | SLC5A5 SSH1 UGT1A6 CD36 CD38 CASR IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 EPG5 | 7.56e-06 | 1048 | 78 | 15 | GO:0014070 |
| GeneOntologyBiologicalProcess | response to nitrogen compound | SEL1L SLC5A5 SSH1 RB1 CD36 TLR4 CASR IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 EPG5 | 1.81e-05 | 1272 | 78 | 16 | GO:1901698 |
| GeneOntologyBiologicalProcess | peptidyl-serine phosphorylation | 2.09e-05 | 307 | 78 | 8 | GO:0018105 | |
| GeneOntologyBiologicalProcess | peptidyl-serine modification | 2.75e-05 | 319 | 78 | 8 | GO:0018209 | |
| GeneOntologyBiologicalProcess | mononuclear cell differentiation | RB1 TLR4 GPR183 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 2.78e-05 | 640 | 78 | 11 | GO:1903131 |
| GeneOntologyBiologicalProcess | innate immune response | RASGRP4 IPO7 CD36 TLR4 N4BP1 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 EPG5 | 5.34e-05 | 1092 | 78 | 14 | GO:0045087 |
| GeneOntologyBiologicalProcess | regulation of protein phosphorylation | IPO7 RASA1 RB1 CD36 PTPRQ TLR4 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 7.94e-05 | 1133 | 78 | 14 | GO:0001932 |
| GeneOntologyBiologicalProcess | defense response to symbiont | RASGRP4 IPO7 CD36 TLR4 N4BP1 ITGAX IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 EPG5 | 8.17e-05 | 1286 | 78 | 15 | GO:0140546 |
| GeneOntologyBiologicalProcess | positive regulation of protein phosphorylation | RASA1 CD36 TLR4 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 8.44e-05 | 724 | 78 | 11 | GO:0001934 |
| GeneOntologyBiologicalProcess | immune effector process | RASGRP4 CD36 TLR4 GPR183 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 8.72e-05 | 859 | 78 | 12 | GO:0002252 |
| GeneOntologyBiologicalProcess | regulation of defense response | RASGRP4 RB1 CD36 TLR4 N4BP1 IFNA4 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 EPG5 | 9.45e-05 | 1006 | 78 | 13 | GO:0031347 |
| GeneOntologyBiologicalProcess | regulation of response to external stimulus | RASGRP4 RB1 CD36 TLR4 CASR N4BP1 GPR183 IFNA4 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 EPG5 | 1.06e-04 | 1316 | 78 | 15 | GO:0032101 |
| GeneOntologyBiologicalProcess | positive regulation of phosphorylation | RASA1 CD36 TLR4 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 1.63e-04 | 780 | 78 | 11 | GO:0042327 |
| GeneOntologyBiologicalProcess | leukocyte differentiation | RB1 TLR4 GPR183 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 1.80e-04 | 789 | 78 | 11 | GO:0002521 |
| GeneOntologyBiologicalProcess | regulation of phosphorylation | IPO7 RASA1 RB1 CD36 PTPRQ TLR4 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 1.82e-04 | 1226 | 78 | 14 | GO:0042325 |
| GeneOntologyBiologicalProcess | lymphocyte differentiation | 1.90e-04 | 537 | 78 | 9 | GO:0030098 | |
| GeneOntologyBiologicalProcess | positive regulation of cytoplasmic mRNA processing body assembly | 2.10e-04 | 6 | 78 | 2 | GO:0010606 | |
| GeneOntologyBiologicalProcess | defense response to other organism | RASGRP4 IPO7 CD36 TLR4 N4BP1 ITGAX IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 EPG5 | 2.21e-04 | 1407 | 78 | 15 | GO:0098542 |
| GeneOntologyBiologicalProcess | response to peptide | CD38 TLR4 CASR IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 PHC1 IFNA16 IFNA17 IFNA21 EPG5 | 2.29e-04 | 1100 | 78 | 13 | GO:1901652 |
| GeneOntologyBiologicalProcess | lymphocyte activation | CD38 TLR4 GPR183 ITGAX IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 2.86e-04 | 976 | 78 | 12 | GO:0046649 |
| GeneOntologyBiologicalProcess | peptidyl-amino acid modification | RASA1 CD36 HHAT TLR4 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 2.86e-04 | 976 | 78 | 12 | GO:0018193 |
| GeneOntologyBiologicalProcess | T cell activation | GPR183 ITGAX IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 3.02e-04 | 701 | 78 | 10 | GO:0042110 |
| GeneOntologyBiologicalProcess | cytokine-mediated signaling pathway | 3.23e-04 | 577 | 78 | 9 | GO:0019221 | |
| GeneOntologyBiologicalProcess | regulation of cytoplasmic mRNA processing body assembly | 3.90e-04 | 8 | 78 | 2 | GO:0010603 | |
| GeneOntologyBiologicalProcess | regulation of protein modification process | IPO7 RASA1 RB1 CD36 PTPRQ TLR4 N4BP1 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 4.02e-04 | 1488 | 78 | 15 | GO:0031399 |
| GeneOntologyBiologicalProcess | cellular response to low-density lipoprotein particle stimulus | 4.31e-04 | 39 | 78 | 3 | GO:0071404 | |
| GeneOntologyBiologicalProcess | positive regulation of phosphate metabolic process | RASA1 CD36 TLR4 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 4.52e-04 | 879 | 78 | 11 | GO:0045937 |
| GeneOntologyBiologicalProcess | positive regulation of phosphorus metabolic process | RASA1 CD36 TLR4 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 4.52e-04 | 879 | 78 | 11 | GO:0010562 |
| GeneOntologyBiologicalProcess | response to lipoprotein particle | 4.65e-04 | 40 | 78 | 3 | GO:0055094 | |
| GeneOntologyBiologicalProcess | positive regulation of cellular component organization | CNOT6 CNOT6L TAPT1 SSH1 AP2B1 RB1 ABCA13 SYNE1 CD36 TLR4 ITGA3 CUL7 TENM2 ARAP1 | 5.48e-04 | 1366 | 78 | 14 | GO:0051130 |
| GeneOntologyBiologicalProcess | cellular response to lipoprotein particle stimulus | 5.76e-04 | 43 | 78 | 3 | GO:0071402 | |
| GeneOntologyBiologicalProcess | response to lipoteichoic acid | 6.23e-04 | 10 | 78 | 2 | GO:0070391 | |
| GeneOntologyBiologicalProcess | cellular response to lipoteichoic acid | 6.23e-04 | 10 | 78 | 2 | GO:0071223 | |
| GeneOntologyBiologicalProcess | hemopoiesis | RASGRP4 RB1 PTPRQ TLR4 GPR183 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 6.31e-04 | 1223 | 78 | 13 | GO:0030097 |
| GeneOntologyBiologicalProcess | response to cytokine | CD38 TLR4 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 PHC1 IFNA16 IFNA17 IFNA21 EPG5 | 7.25e-04 | 1083 | 78 | 12 | GO:0034097 |
| GeneOntologyBiologicalProcess | positive regulation of protein modification process | RASA1 CD36 TLR4 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 7.69e-04 | 937 | 78 | 11 | GO:0031401 |
| GeneOntologyBiologicalProcess | negative regulation of cold-induced thermogenesis | 7.96e-04 | 48 | 78 | 3 | GO:0120163 | |
| GeneOntologyBiologicalProcess | regulation of phosphate metabolic process | IPO7 RASA1 RB1 CD36 PTPRQ TLR4 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 8.09e-04 | 1421 | 78 | 14 | GO:0019220 |
| GeneOntologyBiologicalProcess | regulation of phosphorus metabolic process | IPO7 RASA1 RB1 CD36 PTPRQ TLR4 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 8.20e-04 | 1423 | 78 | 14 | GO:0051174 |
| GeneOntologyBiologicalProcess | positive regulation of B cell proliferation | 9.51e-04 | 51 | 78 | 3 | GO:0030890 | |
| GeneOntologyBiologicalProcess | cellular response to cytokine stimulus | TLR4 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 PHC1 IFNA16 IFNA17 IFNA21 EPG5 | 9.95e-04 | 967 | 78 | 11 | GO:0071345 |
| GeneOntologyBiologicalProcess | cell projection assembly | 1.10e-03 | 685 | 78 | 9 | GO:0030031 | |
| GeneOntologyBiologicalProcess | adaptive immune response | TLR4 GPR183 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 1.20e-03 | 838 | 78 | 10 | GO:0002250 |
| GeneOntologyBiologicalProcess | cellular response to oxidised low-density lipoprotein particle stimulus | 1.25e-03 | 14 | 78 | 2 | GO:0140052 | |
| GeneOntologyBiologicalProcess | leukocyte activation | CD38 TLR4 GPR183 ITGAX IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 1.59e-03 | 1186 | 78 | 12 | GO:0045321 |
| GeneOntologyBiologicalProcess | regulation of cellular component biogenesis | CNOT6 CNOT6L TAPT1 RASA1 SSH1 RB1 SYNE1 CD36 TLR4 TENM2 CYFIP2 ARAP1 | 1.62e-03 | 1189 | 78 | 12 | GO:0044087 |
| GeneOntologyBiologicalProcess | regulation of small GTPase mediated signal transduction | 1.64e-03 | 333 | 78 | 6 | GO:0051056 | |
| GeneOntologyBiologicalProcess | sensory perception of mechanical stimulus | 2.09e-03 | 238 | 78 | 5 | GO:0050954 | |
| Domain | Interferon_alpha/beta/delta | 1.21e-15 | 17 | 76 | 8 | IPR000471 | |
| Domain | Interferon | 1.21e-15 | 17 | 76 | 8 | PF00143 | |
| Domain | IFabd | 1.21e-15 | 17 | 76 | 8 | SM00076 | |
| Domain | INTERFERON_A_B_D | 1.21e-15 | 17 | 76 | 8 | PS00252 | |
| Domain | - | 2.41e-11 | 50 | 76 | 8 | 1.20.1250.10 | |
| Domain | 4_helix_cytokine_core | 2.85e-11 | 51 | 76 | 8 | IPR012351 | |
| Domain | 4_helix_cytokine-like_core | 6.26e-10 | 74 | 76 | 8 | IPR009079 | |
| Domain | Coatomer/calthrin_app_sub_C | 4.50e-04 | 8 | 76 | 2 | IPR009028 | |
| Domain | Coatomer/clathrin_app_Ig-like | 1.05e-03 | 12 | 76 | 2 | IPR013041 | |
| Domain | Clathrin/coatomer_adapt-like_N | 1.66e-03 | 15 | 76 | 2 | IPR002553 | |
| Domain | Adaptin_N | 1.66e-03 | 15 | 76 | 2 | PF01602 | |
| Domain | EGF_extracell | 1.88e-03 | 60 | 76 | 3 | IPR013111 | |
| Domain | EGF_2 | 1.88e-03 | 60 | 76 | 3 | PF07974 | |
| Domain | Integrin_alpha_C_CS | 1.89e-03 | 16 | 76 | 2 | IPR018184 | |
| Domain | Integrin_alpha-2 | 2.40e-03 | 18 | 76 | 2 | IPR013649 | |
| Domain | Integrin_alpha2 | 2.40e-03 | 18 | 76 | 2 | PF08441 | |
| Domain | Integrin_alpha | 2.40e-03 | 18 | 76 | 2 | IPR000413 | |
| Domain | INTEGRIN_ALPHA | 2.40e-03 | 18 | 76 | 2 | PS00242 | |
| Domain | Int_alpha_beta-p | 2.67e-03 | 19 | 76 | 2 | IPR013519 | |
| Domain | Int_alpha | 2.67e-03 | 19 | 76 | 2 | SM00191 | |
| Domain | FG_GAP | 3.58e-03 | 22 | 76 | 2 | PS51470 | |
| Domain | C_TYPE_LECTIN_1 | 4.25e-03 | 80 | 76 | 3 | PS00615 | |
| Domain | FG-GAP | 4.26e-03 | 24 | 76 | 2 | PF01839 | |
| Domain | FG-GAP | 4.26e-03 | 24 | 76 | 2 | IPR013517 | |
| Domain | Integrin_dom | 4.61e-03 | 25 | 76 | 2 | IPR032695 | |
| Domain | Lectin_C | 4.87e-03 | 84 | 76 | 3 | PF00059 | |
| Domain | CLECT | 4.87e-03 | 84 | 76 | 3 | SM00034 | |
| Domain | - | 4.99e-03 | 26 | 76 | 2 | 3.60.10.10 | |
| Domain | Exo_endo_phos | 4.99e-03 | 26 | 76 | 2 | PF03372 | |
| Domain | C_TYPE_LECTIN_2 | 5.03e-03 | 85 | 76 | 3 | PS50041 | |
| Domain | C-type_lectin-like | 5.20e-03 | 86 | 76 | 3 | IPR001304 | |
| Domain | Endo/exonuclease/phosphatase | 5.37e-03 | 27 | 76 | 2 | IPR005135 | |
| Domain | EGF_LAM_2 | 6.60e-03 | 30 | 76 | 2 | PS50027 | |
| Domain | EGF_LAM_1 | 6.60e-03 | 30 | 76 | 2 | PS01248 | |
| Domain | - | 7.26e-03 | 97 | 76 | 3 | 3.10.100.10 | |
| Domain | PSI | 7.49e-03 | 32 | 76 | 2 | PF01437 | |
| Domain | Plexin_repeat | 7.49e-03 | 32 | 76 | 2 | IPR002165 | |
| Domain | C-type_lectin-like/link | 7.68e-03 | 99 | 76 | 3 | IPR016186 | |
| Pathway | KEGG_MEDICUS_PATHOGEN_HIV_TAT_TO_TLR2_4_NFKB_SIGNALING_PATHWAY | 2.70e-15 | 17 | 64 | 8 | M47564 | |
| Pathway | KEGG_MEDICUS_REFERENCE_CGAS_STING_SIGNALING_PATHWAY | 4.84e-15 | 18 | 64 | 8 | M47539 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TLR3_IRF7_SIGNALING_PATHWAY | 8.34e-15 | 19 | 64 | 8 | M47450 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TLR7_9_IRF7_SIGNALING_PATHWAY | 1.38e-14 | 20 | 64 | 8 | M47617 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TYPE_II_INTERFERON_TO_JAK_STAT_SIGNALING_PATHWAY | 2.23e-14 | 21 | 64 | 8 | M47909 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TLR7_8_9_IRF5_SIGNALING_PATHWAY | 3.49e-14 | 22 | 64 | 8 | M47897 | |
| Pathway | KEGG_MEDICUS_REFERENCE_RIG_I_NFKB_SIGNALING_PATHWAY | 3.49e-14 | 22 | 64 | 8 | M47616 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TYPE_I_IFN_SIGNALING_PATHWAY | 5.33e-14 | 23 | 64 | 8 | M47452 | |
| Pathway | REACTOME_REGULATION_OF_IFNA_IFNB_SIGNALING | 5.33e-14 | 23 | 64 | 8 | MM15634 | |
| Pathway | KEGG_MEDICUS_REFERENCE_RIG_I_IRF7_3_SIGNALING_PATHWAY | 7.97e-14 | 24 | 64 | 8 | M47576 | |
| Pathway | KEGG_MEDICUS_REFERENCE_MDA5_IRF7_3_SIGNALING_PATHWAY | 7.97e-14 | 24 | 64 | 8 | M47782 | |
| Pathway | KEGG_MEDICUS_REFERENCE_TYPE_I_INTERFERON_TO_JAK_STAT_SIGNALING_PATHWAY | 7.97e-14 | 24 | 64 | 8 | M47908 | |
| Pathway | REACTOME_REGULATION_OF_IFNA_IFNB_SIGNALING | 1.68e-13 | 26 | 64 | 8 | M982 | |
| Pathway | REACTOME_TRAF6_MEDIATED_IRF7_ACTIVATION | 6.21e-13 | 30 | 64 | 8 | M936 | |
| Pathway | WP_SARS_CORONAVIRUS_AND_INNATE_IMMUNITY | 8.34e-13 | 31 | 64 | 8 | M39897 | |
| Pathway | KEGG_MEDICUS_REFERENCE_IFN_RIPK1_3_SIGNALING_PATHWAY | 8.34e-13 | 31 | 64 | 8 | M47964 | |
| Pathway | BIOCARTA_IFNA_PATHWAY | 1.37e-12 | 19 | 64 | 7 | MM1571 | |
| Pathway | REACTOME_INTERFERON_ALPHA_BETA_SIGNALING | 1.90e-12 | 34 | 64 | 8 | MM15631 | |
| Pathway | REACTOME_EVASION_BY_RSV_OF_HOST_INTERFERON_RESPONSES | 2.45e-12 | 35 | 64 | 8 | M48246 | |
| Pathway | KEGG_REGULATION_OF_AUTOPHAGY | 2.45e-12 | 35 | 64 | 8 | M6382 | |
| Pathway | WP_INTERFERONMEDIATED_SIGNALING | 3.99e-12 | 37 | 64 | 8 | M39785 | |
| Pathway | BIOCARTA_CYTOKINE_PATHWAY | 3.11e-11 | 28 | 64 | 7 | MM1378 | |
| Pathway | KEGG_AUTOIMMUNE_THYROID_DISEASE | 7.38e-11 | 52 | 64 | 8 | M13103 | |
| Pathway | BIOCARTA_INFLAM_PATHWAY | 1.10e-10 | 33 | 64 | 7 | MM1379 | |
| Pathway | KEGG_CYTOSOLIC_DNA_SENSING_PATHWAY | 1.18e-10 | 55 | 64 | 8 | M11844 | |
| Pathway | WP_CYTOKINES_AND_INFLAMMATORY_RESPONSE | 3.89e-10 | 39 | 64 | 7 | MM15914 | |
| Pathway | PID_CD8_TCR_DOWNSTREAM_PATHWAY | 4.73e-10 | 65 | 64 | 8 | M272 | |
| Pathway | REACTOME_RSV_HOST_INTERACTIONS | 5.24e-10 | 98 | 64 | 9 | M48247 | |
| Pathway | BIOCARTA_IL1R_PATHWAY | 5.65e-10 | 41 | 64 | 7 | MM1493 | |
| Pathway | KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY | 7.52e-10 | 102 | 64 | 9 | M3261 | |
| Pathway | WP_TOLLLIKE_RECEPTOR_SIGNALING | 8.21e-10 | 103 | 64 | 9 | M39434 | |
| Pathway | KEGG_RIG_I_LIKE_RECEPTOR_SIGNALING_PATHWAY | 9.76e-10 | 71 | 64 | 8 | M15913 | |
| Pathway | WP_CYTOSOLIC_DNASENSING_PATHWAY | 1.22e-09 | 73 | 64 | 8 | M39837 | |
| Pathway | REACTOME_INTERFERON_ALPHA_BETA_SIGNALING | 2.10e-09 | 78 | 64 | 8 | M973 | |
| Pathway | REACTOME_DDX58_IFIH1_MEDIATED_INDUCTION_OF_INTERFERON_ALPHA_BETA | 3.14e-09 | 82 | 64 | 8 | M1002 | |
| Pathway | REACTOME_RESPIRATORY_SYNCYTIAL_VIRUS_INFECTION_PATHWAY | 3.22e-09 | 120 | 64 | 9 | M48233 | |
| Pathway | KEGG_ANTIGEN_PROCESSING_AND_PRESENTATION | 5.55e-09 | 88 | 64 | 8 | M16004 | |
| Pathway | WP_MEASLES_VIRUS_INFECTION | 9.75e-09 | 136 | 64 | 9 | M42547 | |
| Pathway | WP_HEPATITIS_B_INFECTION | 2.44e-08 | 151 | 64 | 9 | M39801 | |
| Pathway | REACTOME_SARS_COV_2_ACTIVATES_MODULATES_INNATE_AND_ADAPTIVE_IMMUNE_RESPONSES | 9.48e-08 | 126 | 64 | 8 | M45009 | |
| Pathway | WP_OVERVIEW_OF_PROINFLAMMATORY_AND_PROFIBROTIC_MEDIATORS | 1.01e-07 | 127 | 64 | 8 | M42533 | |
| Pathway | WP_IL2_SIGNALING_PATHWAY | 1.25e-07 | 87 | 64 | 7 | MM15915 | |
| Pathway | KEGG_NATURAL_KILLER_CELL_MEDIATED_CYTOTOXICITY | 1.81e-07 | 137 | 64 | 8 | M5669 | |
| Pathway | REACTOME_INTERFERON_SIGNALING | 1.92e-07 | 138 | 64 | 8 | MM15635 | |
| Pathway | KEGG_JAK_STAT_SIGNALING_PATHWAY | 4.68e-07 | 155 | 64 | 8 | M17411 | |
| Pathway | REACTOME_FACTORS_INVOLVED_IN_MEGAKARYOCYTE_DEVELOPMENT_AND_PLATELET_PRODUCTION | 9.45e-07 | 170 | 64 | 8 | M941 | |
| Pathway | WP_FOCAL_ADHESION_PI3KAKTMTOR_SIGNALING_PATHWAY | ITGA3 ITGAX IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 1.91e-06 | 326 | 64 | 10 | MM15917 |
| Pathway | WP_PI3KAKT_SIGNALING | TLR4 ITGA3 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 2.71e-06 | 339 | 64 | 10 | M39736 |
| Pathway | REACTOME_SARS_COV_2_HOST_INTERACTIONS | 3.70e-06 | 204 | 64 | 8 | M45011 | |
| Pathway | REACTOME_INNATE_IMMUNE_SYSTEM | MGAM RASGRP4 ABCA13 CD36 TLR4 N4BP1 ITGAX MUC6 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 CYFIP2 IFNA16 IFNA17 IFNA21 | 7.46e-06 | 1128 | 64 | 17 | M1036 |
| Pathway | REACTOME_SARS_COV_2_INFECTION | 7.62e-06 | 299 | 64 | 9 | M41727 | |
| Pathway | WP_CANCER_PATHWAYS | RASGRP4 RB1 ITGA3 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 1.54e-05 | 507 | 64 | 11 | M48302 |
| Pathway | KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION | 2.43e-05 | 264 | 64 | 8 | M9809 | |
| Pathway | REACTOME_INTERFERON_SIGNALING | 3.09e-05 | 273 | 64 | 8 | M983 | |
| Pathway | REACTOME_SARS_COV_INFECTIONS | AP2B1 RB1 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 4.73e-05 | 471 | 64 | 10 | M39009 |
| Pathway | REACTOME_HEMOSTASIS | CD36 ITGA3 ITGAX IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 2.15e-04 | 679 | 64 | 11 | M8395 |
| Pathway | REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM | 2.63e-04 | 472 | 64 | 9 | MM14539 | |
| Pathway | REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM | CD36 N4BP1 ITGAX IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 7.68e-04 | 789 | 64 | 11 | M1060 |
| Pathway | WP_INDUCTION_OF_AUTOPHAGY_AND_TOLLLIKE_RECEPTOR_SIGNALING_BY_GRAPHENE_OXIDE | 1.09e-03 | 11 | 64 | 2 | M48068 | |
| Pathway | REACTOME_VIRAL_INFECTION_PATHWAYS | AP2B1 RB1 TLR4 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 2.00e-03 | 888 | 64 | 11 | M48034 |
| Pathway | KEGG_MEDICUS_REFERENCE_AUTOPHAGOSOME_AND_LYSOSOME_FUSION_TETHERING_FACTOR | 2.34e-03 | 16 | 64 | 2 | M47978 | |
| Pathway | REACTOME_TP53_REGULATES_TRANSCRIPTION_OF_ADDITIONAL_CELL_CYCLE_GENES_WHOSE_EXACT_ROLE_IN_THE_P53_PATHWAY_REMAIN_UNCERTAIN | 2.96e-03 | 18 | 64 | 2 | MM15336 | |
| Pathway | REACTOME_IRAK4_DEFICIENCY_TLR2_4 | 2.96e-03 | 18 | 64 | 2 | M27464 | |
| Pathway | REACTOME_INFECTIOUS_DISEASE | AP2B1 RB1 TLR4 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 CYFIP2 IFNA16 IFNA17 IFNA21 | 3.08e-03 | 1081 | 64 | 12 | M27548 |
| Pubmed | 2.17e-19 | 12 | 78 | 8 | 16565497 | ||
| Pubmed | Evolution of the interferon alpha gene family in eutherian mammals. | 2.17e-19 | 12 | 78 | 8 | 17512142 | |
| Pubmed | Repression of the murine interferon alpha 11 gene: identification of negatively acting sequences. | 2.17e-19 | 12 | 78 | 8 | 1886773 | |
| Pubmed | The physical separation of Lps and Ifa loci in BXH recombinant inbred mice. | 2.17e-19 | 12 | 78 | 8 | 2572648 | |
| Pubmed | Multiple pathways of interferon-induced gene expression in murine macrophages. | 2.17e-19 | 12 | 78 | 8 | 7684767 | |
| Pubmed | Negative regulation of the alpha interferon-induced antiviral response by the Ras/Raf/MEK pathway. | 2.17e-19 | 12 | 78 | 8 | 16611902 | |
| Pubmed | Interferon-alpha subtype 11 activates NK cells and enables control of retroviral infection. | 2.17e-19 | 12 | 78 | 8 | 22912583 | |
| Pubmed | Structure and expression of a new murine interferon-alpha gene: MuIFN-alpha I9. | 2.17e-19 | 12 | 78 | 8 | 3758677 | |
| Pubmed | 2.17e-19 | 12 | 78 | 8 | 8245849 | ||
| Pubmed | 2.17e-19 | 12 | 78 | 8 | 11846978 | ||
| Pubmed | Identification of distal silencing elements in the murine interferon-A11 gene promoter. | 2.17e-19 | 12 | 78 | 8 | 8760352 | |
| Pubmed | Role of interferons in the regulation of cell proliferation, differentiation, and development. | 2.17e-19 | 12 | 78 | 8 | 7530016 | |
| Pubmed | 2.17e-19 | 12 | 78 | 8 | 9794206 | ||
| Pubmed | 2.17e-19 | 12 | 78 | 8 | 17451966 | ||
| Pubmed | 4.32e-19 | 22 | 78 | 9 | 23100517 | ||
| Pubmed | Characterization of interferon-alpha 13, a novel constitutive murine interferon-alpha subtype. | 5.64e-19 | 13 | 78 | 8 | 12930842 | |
| Pubmed | Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. | 5.64e-19 | 13 | 78 | 8 | 2014240 | |
| Pubmed | 5.64e-19 | 13 | 78 | 8 | 18005734 | ||
| Pubmed | 5.64e-19 | 13 | 78 | 8 | 12050368 | ||
| Pubmed | Isolation and bacterial expression of a murine alpha leukocyte interferon gene. | 5.64e-19 | 13 | 78 | 8 | 6094686 | |
| Pubmed | 5.64e-19 | 13 | 78 | 8 | 1655578 | ||
| Pubmed | 5.64e-19 | 13 | 78 | 8 | 2471809 | ||
| Pubmed | 5.64e-19 | 13 | 78 | 8 | 8438572 | ||
| Pubmed | 5.64e-19 | 13 | 78 | 8 | 9343822 | ||
| Pubmed | Evidence for a different susceptibility of primate lentiviruses to type I interferons. | 5.64e-19 | 13 | 78 | 8 | 23255800 | |
| Pubmed | 5.64e-19 | 13 | 78 | 8 | 7523540 | ||
| Pubmed | 5.64e-19 | 13 | 78 | 8 | 19706714 | ||
| Pubmed | Organization, structure and expression of murine interferon alpha genes. | 5.64e-19 | 13 | 78 | 8 | 2987810 | |
| Pubmed | 5.64e-19 | 13 | 78 | 8 | 19130550 | ||
| Pubmed | 5.64e-19 | 13 | 78 | 8 | 22739040 | ||
| Pubmed | 5.64e-19 | 13 | 78 | 8 | 9181467 | ||
| Pubmed | Sequencing and bacterial expression of a novel murine alpha interferon gene. | 5.64e-19 | 13 | 78 | 8 | 18726328 | |
| Pubmed | 5.64e-19 | 13 | 78 | 8 | 18572754 | ||
| Pubmed | Interferon induction by HIV glycoprotein 120: role of the V3 loop. | 1.31e-18 | 14 | 78 | 8 | 7526537 | |
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 19559726 | ||
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 15240719 | ||
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 16418394 | ||
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 18272764 | ||
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 11884139 | ||
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 19004943 | ||
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 2552026 | ||
| Pubmed | Modulation of interferon-mediated inhibition of human immunodeficiency virus type 1 by Tat. | 1.31e-18 | 14 | 78 | 8 | 7532202 | |
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 18200012 | ||
| Pubmed | Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. | 1.31e-18 | 14 | 78 | 8 | 18200009 | |
| Pubmed | A structural basis for interferon-alpha-receptor interactions. | 1.31e-18 | 14 | 78 | 8 | 17517919 | |
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 14983024 | ||
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 25972534 | ||
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 7583919 | ||
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 2987811 | ||
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 21172865 | ||
| Pubmed | Characterization of the murine alpha interferon gene family. | 1.31e-18 | 14 | 78 | 8 | 15254193 | |
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 16278001 | ||
| Pubmed | Recombinant glycoprotein 120 of human immunodeficiency virus is a potent interferon inducer. | 1.31e-18 | 14 | 78 | 8 | 1381203 | |
| Pubmed | 1.31e-18 | 14 | 78 | 8 | 8345204 | ||
| Pubmed | The RIPK1 death domain restrains ZBP1- and TRIF-mediated cell death and inflammation. | 2.70e-18 | 26 | 78 | 9 | 38744293 | |
| Pubmed | 2.81e-18 | 15 | 78 | 8 | 8786318 | ||
| Pubmed | 2.81e-18 | 15 | 78 | 8 | 15684736 | ||
| Pubmed | 2.81e-18 | 15 | 78 | 8 | 9520456 | ||
| Pubmed | Are CD4 and Fas peptide identities of gp120 relevant to the molecular basis of AIDS pathogenesis? | 2.81e-18 | 15 | 78 | 8 | 17180012 | |
| Pubmed | Role of the Akt pathway in mRNA translation of interferon-stimulated genes. | 2.81e-18 | 15 | 78 | 8 | 18339807 | |
| Pubmed | Interferon induction by HIV-1-infected cells: a possible role of sulfatides or related glycolipids. | 2.81e-18 | 15 | 78 | 8 | 8661419 | |
| Pubmed | Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo. | 5.61e-18 | 16 | 78 | 8 | 22315404 | |
| Pubmed | Coordinate induction of interferon alpha and gamma by recombinant HIV-1 glycoprotein 120. | 5.61e-18 | 16 | 78 | 8 | 7904170 | |
| Pubmed | Sialoadhesin expressed on IFN-induced monocytes binds HIV-1 and enhances infectivity. | 5.61e-18 | 16 | 78 | 8 | 18414664 | |
| Pubmed | Insect baculoviruses strongly potentiate adaptive immune responses by inducing type I IFN. | 5.94e-18 | 28 | 78 | 9 | 17277142 | |
| Pubmed | 1.06e-17 | 17 | 78 | 8 | 22814248 | ||
| Pubmed | Characterization of the type I interferon locus and identification of novel genes. | 1.06e-17 | 17 | 78 | 8 | 15233997 | |
| Pubmed | 1.90e-17 | 18 | 78 | 8 | 1905933 | ||
| Pubmed | 3.28e-17 | 19 | 78 | 8 | 7511078 | ||
| Pubmed | 3.28e-17 | 19 | 78 | 8 | 7815507 | ||
| Pubmed | 3.28e-17 | 19 | 78 | 8 | 17360657 | ||
| Pubmed | Translational regulation by HIV leader RNA, TAT, and interferon-inducible enzymes. | 3.28e-17 | 19 | 78 | 8 | 1708818 | |
| Pubmed | 3.28e-17 | 19 | 78 | 8 | 1385305 | ||
| Pubmed | 3.28e-17 | 19 | 78 | 8 | 17942529 | ||
| Pubmed | TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B. | 5.45e-17 | 20 | 78 | 8 | 11694501 | |
| Pubmed | 5.45e-17 | 20 | 78 | 8 | 8764000 | ||
| Pubmed | 7.09e-17 | 11 | 78 | 7 | 18835032 | ||
| Pubmed | High-affinity binding of 125I-labelled mouse interferon to a specific cell surface receptor. | 7.09e-17 | 11 | 78 | 7 | 6444699 | |
| Pubmed | Structural and functional neuropathology in transgenic mice with CNS expression of IFN-alpha. | 7.09e-17 | 11 | 78 | 7 | 10448195 | |
| Pubmed | IFN-alpha can both protect against and promote the development of type 1 diabetes. | 7.09e-17 | 11 | 78 | 7 | 19120292 | |
| Pubmed | Effect of interferon-alpha on immediate early gene expression of murine cytomegalovirus. | 7.09e-17 | 11 | 78 | 7 | 8389790 | |
| Pubmed | The mouse IFN-alpha (Ifa) locus: correlation of physical and linkage maps by in situ hybridization. | 7.09e-17 | 11 | 78 | 7 | 3456887 | |
| Pubmed | Mechanism of SUMOylation-Mediated Regulation of Type I IFN Expression. | 7.09e-17 | 11 | 78 | 7 | 36681180 | |
| Pubmed | Type I interferon dependence of plasmacytoid dendritic cell activation and migration. | 7.09e-17 | 11 | 78 | 7 | 15795237 | |
| Pubmed | 7.09e-17 | 11 | 78 | 7 | 9794439 | ||
| Pubmed | 7.09e-17 | 11 | 78 | 7 | 25310498 | ||
| Pubmed | 8.79e-17 | 21 | 78 | 8 | 9108403 | ||
| Pubmed | 1.38e-16 | 22 | 78 | 8 | 7913356 | ||
| Pubmed | 1.38e-16 | 22 | 78 | 8 | 16160188 | ||
| Pubmed | Regulation of effector and memory T-cell functions by type I interferon. | 1.70e-16 | 12 | 78 | 7 | 21320124 | |
| Pubmed | MAVS Deficiency Is Associated With a Reduced T Cell Response Upon Secondary RSV Infection in Mice. | 1.70e-16 | 12 | 78 | 7 | 33123150 | |
| Pubmed | A novel anti-viral role for STAT3 in IFN-α signalling responses. | 1.70e-16 | 12 | 78 | 7 | 27988795 | |
| Pubmed | 1.70e-16 | 12 | 78 | 7 | 8656058 | ||
| Pubmed | Developmental control of IFN-alpha expression in murine embryos. | 1.70e-16 | 12 | 78 | 7 | 7925651 | |
| Pubmed | The role of type 1 interferons in coagulation induced by gram-negative bacteria. | 1.70e-16 | 12 | 78 | 7 | 32016282 | |
| Pubmed | 1.70e-16 | 12 | 78 | 7 | 6188104 | ||
| Pubmed | Ligation of CD180 inhibits IFN-α signaling in a Lyn-PI3K-BTK-dependent manner in B cells. | 1.70e-16 | 12 | 78 | 7 | 26277892 | |
| Pubmed | 1.70e-16 | 12 | 78 | 7 | 6689487 | ||
| Pubmed | Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. | 1.70e-16 | 12 | 78 | 7 | 18716002 | |
| Pubmed | 1.70e-16 | 12 | 78 | 7 | 30967261 | ||
| Interaction | IFNA13 interactions | 3.24e-10 | 11 | 77 | 5 | int:IFNA13 | |
| Interaction | IFNA4 interactions | 4.80e-07 | 41 | 77 | 5 | int:IFNA4 | |
| Interaction | IFNA5 interactions | 1.37e-06 | 22 | 77 | 4 | int:IFNA5 | |
| Interaction | IFNA16 interactions | 1.86e-06 | 7 | 77 | 3 | int:IFNA16 | |
| Interaction | UBR3 interactions | 2.16e-06 | 99 | 77 | 6 | int:UBR3 | |
| Interaction | IFNA7 interactions | 4.43e-06 | 9 | 77 | 3 | int:IFNA7 | |
| Interaction | IFIT1 interactions | 4.56e-06 | 64 | 77 | 5 | int:IFIT1 | |
| Interaction | IFNA1 interactions | 2.90e-05 | 16 | 77 | 3 | int:IFNA1 | |
| Cytoband | 9p22 | 5.07e-17 | 25 | 78 | 8 | 9p22 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr9p21 | 4.51e-11 | 124 | 78 | 8 | chr9p21 | |
| Cytoband | Ensembl 112 genes in cytogenetic band chr16q12 | 7.38e-04 | 103 | 78 | 3 | chr16q12 | |
| GeneFamily | Interferons | 4.99e-14 | 32 | 56 | 8 | 598 | |
| GeneFamily | Hyalectan proteoglycans|V-set domain containing|Sushi domain containing|C-type lectin domain containing | 2.76e-04 | 41 | 56 | 3 | 1298 | |
| GeneFamily | CCR4-NOT transcription complex | 5.09e-04 | 11 | 56 | 2 | 1023 | |
| GeneFamily | CD molecules|Integrin alpha subunits | 1.40e-03 | 18 | 56 | 2 | 1160 | |
| Coexpression | ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_NAIVE_NOT_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP | 1.98e-15 | 39 | 77 | 9 | M41095 | |
| Coexpression | LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_DT_ANTIBODY_CORRELATION_PROFILE_3DY_UP | 1.21e-12 | 27 | 77 | 7 | M40935 | |
| Coexpression | SHIN_B_CELL_LYMPHOMA_CLUSTER_5 | 2.12e-12 | 29 | 77 | 7 | MM586 | |
| Coexpression | WORSCHECH_TUMOR_REJECTION_UP | 9.34e-11 | 80 | 77 | 8 | MM1229 | |
| Coexpression | LEE_CALORIE_RESTRICTION_NEOCORTEX_DN | 1.53e-10 | 85 | 77 | 8 | MM684 | |
| Coexpression | GROSS_HYPOXIA_VIA_HIF1A_DN | 1.78e-10 | 131 | 77 | 9 | MM1127 | |
| Coexpression | ERWIN_COHEN_PBMC_TC_83_AGE_18_45YO_RESPONDERS_PREVIOUSLY_IMMUNIZED_24HR_DEG_CANONICAL_PATHWAY_MEMBERS_UP | 6.64e-10 | 34 | 77 | 6 | M41094 | |
| Coexpression | LEE_AGING_NEOCORTEX_DN | 3.82e-09 | 80 | 77 | 7 | MM646 | |
| Coexpression | LEE_CALORIE_RESTRICTION_NEOCORTEX_UP | 6.92e-09 | 87 | 77 | 7 | MM652 | |
| Coexpression | IWANAGA_CARCINOGENESIS_BY_KRAS_PTEN_UP | 1.15e-08 | 210 | 77 | 9 | MM751 | |
| Coexpression | LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_POLYSACCHARIDE_ANTIBODY_CORRELATION_PROFILE_3DY_DN | 1.22e-07 | 16 | 77 | 4 | M40964 | |
| Coexpression | LI_PBMC_MENOMUNE_A_C_Y_W_135_AGE_18_45YO_3DY_DN | 2.58e-07 | 19 | 77 | 4 | M40933 | |
| Coexpression | RAO_BOUND_BY_SALL4_ISOFORM_B | IPO7 CD38 ITGA3 IFNA4 IFNA5 IFNA7 IFNA8 IFNA10 IFNA16 IFNA17 IFNA21 | 1.08e-06 | 584 | 77 | 11 | MM1080 |
| Coexpression | GSE37416_12H_VS_48H_F_TULARENSIS_LVS_NEUTROPHIL_UP | 2.01e-06 | 199 | 77 | 7 | M5359 | |
| Coexpression | LI_PBMC_MENACTRA_AGE_18_45YO_ANTI_POLYSACCHARIDE_ANTIBODY_CORRELATION_PROFILE_3DY_UP | 2.33e-06 | 32 | 77 | 4 | M40934 | |
| Coexpression | NABA_SECRETED_FACTORS | 6.83e-06 | 338 | 77 | 8 | MM17064 | |
| Coexpression | NABA_SECRETED_FACTORS | 7.61e-06 | 343 | 77 | 8 | M5883 | |
| Coexpression | FRIDMAN_IMMORTALIZATION_DN | 1.25e-04 | 33 | 77 | 3 | M7404 | |
| Coexpression | GSE2935_UV_INACTIVATED_VS_LIVE_SENDAI_VIRUS_INF_MACROPHAGE_DN | 1.91e-04 | 180 | 77 | 5 | M6317 | |
| Coexpression | NAKAYA_PLASMACYTOID_DENDRITIC_CELL_FLUMIST_AGE_18_50YO_7DY_UP | SEL1L IPO7 RASA1 AP2B1 INPP4A DENND4B DHDDS CHD9 N4BP1 GPR183 CEP57 CYFIP2 | 2.11e-04 | 1215 | 77 | 12 | M41122 |
| Coexpression | XIE_TRASTUZUMAB_CARDIOTOXICITY_MMU_MIR_690_GENES | 2.36e-04 | 8 | 77 | 2 | MM17507 | |
| Coexpression | FEKIR_HEPARG_SPHERE_VS_HEPARG_UP | 2.44e-04 | 103 | 77 | 4 | M48358 | |
| Coexpression | GSE25088_CTRL_VS_ROSIGLITAZONE_STIM_STAT6_KO_MACROPHAGE_UP | 2.58e-04 | 192 | 77 | 5 | M7932 | |
| Coexpression | GSE18791_UNSTIM_VS_NEWCATSLE_VIRUS_DC_10H_DN | 2.90e-04 | 197 | 77 | 5 | M4294 | |
| Coexpression | GSE5542_UNTREATED_VS_IFNG_TREATED_EPITHELIAL_CELLS_24H_UP | 2.97e-04 | 198 | 77 | 5 | M6522 | |
| Coexpression | GSE22886_NAIVE_BCELL_VS_DC_UP | 2.97e-04 | 198 | 77 | 5 | M4483 | |
| Coexpression | GSE37416_12H_VS_24H_F_TULARENSIS_LVS_NEUTROPHIL_UP | 3.04e-04 | 199 | 77 | 5 | M5357 | |
| Coexpression | NABA_MATRISOME_ASSOCIATED | 3.09e-04 | 738 | 77 | 9 | MM17058 | |
| Coexpression | FISCHER_DIRECT_P53_TARGETS_META_ANALYSIS | 3.11e-04 | 311 | 77 | 6 | M61 | |
| Coexpression | GSE41867_DAY8_VS_DAY15_LCMV_CLONE13_EFFECTOR_CD8_TCELL_UP | 3.11e-04 | 200 | 77 | 5 | M9449 | |
| Coexpression | GSE369_SOCS3_KO_VS_WT_LIVER_POST_IL6_INJECTION_DN | 3.11e-04 | 200 | 77 | 5 | M5966 | |
| Coexpression | GSE369_PRE_VS_POST_IL6_INJECTION_SOCS3_KO_LIVER_DN | 3.11e-04 | 200 | 77 | 5 | M5977 | |
| Coexpression | GSE19401_NAIVE_VS_IMMUNIZED_MOUSE_PLN_FOLLICULAR_DC_DN | 3.11e-04 | 200 | 77 | 5 | M7658 | |
| Coexpression | GSE9650_NAIVE_VS_MEMORY_CD8_TCELL_DN | 3.11e-04 | 200 | 77 | 5 | M5832 | |
| Coexpression | GSE27859_DC_VS_CD11C_INT_F480_INT_DC_UP | 3.11e-04 | 200 | 77 | 5 | M8596 | |
| Coexpression | GSE32986_UNSTIM_VS_CURDLAN_HIGHDOSE_STIM_DC_DN | 3.11e-04 | 200 | 77 | 5 | M8618 | |
| Coexpression | KAECH_NAIVE_VS_MEMORY_CD8_TCELL_DN | 3.11e-04 | 200 | 77 | 5 | M3022 | |
| Coexpression | NABA_MATRISOME_ASSOCIATED | 3.52e-04 | 751 | 77 | 9 | M5885 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.76e-11 | 184 | 78 | 9 | 2cbed6462fea2622871bb7e49b0df3d984239281 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.76e-11 | 184 | 78 | 9 | ea7a7e2bac46d4d2c31a5d576b38a032b5335062 | |
| ToppCell | facs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 3.76e-11 | 184 | 78 | 9 | 2b19a8c5f823e00812908b23e66bb4e563278aff | |
| ToppCell | COVID_non-vent-Lymphocytic-ILC|COVID_non-vent / Disease condition, Lineage, Cell class and subclass | 6.03e-08 | 199 | 78 | 7 | df4f7d5be099e3e6054f3b812ccf70251664e4c0 | |
| ToppCell | COVID_non-vent-Lymphocytic-ILC-NK_cell|COVID_non-vent / Disease condition, Lineage, Cell class and subclass | 6.03e-08 | 199 | 78 | 7 | ed35d747f11f6ea6a5cb7061057f0a98d9e0db99 | |
| ToppCell | COVID-19-COVID-19_Mild-Lymphocyte-T/NK-NK_activated|COVID-19_Mild / Disease, condition lineage and cell class | 1.41e-06 | 200 | 78 | 6 | 2281debd86e5d92e8fe0397aec9ef670800f7471 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Vascular-Mural_cell-SMC-G|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 6.26e-06 | 148 | 78 | 5 | e514b7cf412ddbee249894e089e2204c67bcdbce | |
| ToppCell | facs-Lung-24m-Endothelial-capillary_endothelial-capillary_endothelial_cell-capillary_type_1_endothelial_cell|24m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype | 9.71e-06 | 162 | 78 | 5 | bf886e22ff2a20353499004b53f25fb9e6574896 | |
| ToppCell | facs-Diaphragm-Limb_Muscle-24m|Diaphragm / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.19e-05 | 169 | 78 | 5 | 12bdc709bc000d7f9061ecd9fbd57233eaacb7e2 | |
| ToppCell | BALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c07-TYROBP|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.41e-05 | 175 | 78 | 5 | 8fb8c4b9e2d9b7d737f59cd9bd3dc2bca5a8dfc4 | |
| ToppCell | PBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.49e-05 | 177 | 78 | 5 | d3e6c768b88b7906f3c7fdd00ba20842212c14b1 | |
| ToppCell | PBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01) | 1.49e-05 | 177 | 78 | 5 | f8f101c772c043636bedd6b2ec81409b1d2599bf | |
| ToppCell | COVID-19_Mild-Lymphoid_T/NK-NK_activated|COVID-19_Mild / Disease group, lineage and cell class | 1.49e-05 | 177 | 78 | 5 | 6978a22fef40c8b455342373abe7593f5ede0fa4 | |
| ToppCell | PBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated|Mild / Location, Disease Group, Cell group, Cell class (2021.03.09) | 1.49e-05 | 177 | 78 | 5 | 936ab2b180a052387124f68d0c7f41c0b164e748 | |
| ToppCell | PBMC-Mild-Lymphocyte-T/NK-NK_cell-NK_activated-|Mild / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09) | 1.49e-05 | 177 | 78 | 5 | d5aeda113afaa2425874394610344570c9078478 | |
| ToppCell | COVID-19-kidney-NK|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.66e-05 | 181 | 78 | 5 | 8906ee8a7a1616dfe8c3b5c73988416641213629 | |
| ToppCell | COVID-19-kidney-PCT-S1|COVID-19 / Disease (COVID-19 only), tissue and cell type | 1.75e-05 | 183 | 78 | 5 | 6878d14026c3df6aa12e45dfad94b32fa9d9b0b7 | |
| ToppCell | COVID-19_Mild-NK_activated|COVID-19_Mild / Disease condition and Cell class | 1.75e-05 | 183 | 78 | 5 | 22bd05135906d0ecc4ba8c2e0a666093d1bf3b8f | |
| ToppCell | IPF-Lymphoid-NK|Lymphoid / Disease state, Lineage and Cell class | 2.15e-05 | 191 | 78 | 5 | f2ddc0962007d7a4e78fbd916ebb62fc557d480a | |
| ToppCell | 3'_v3-lymph-node_spleen-Lymphocytic_NK|lymph-node_spleen / Manually curated celltypes from each tissue | 2.26e-05 | 193 | 78 | 5 | e325cf49e159c6be205ed93adaa09efdd0c122b4 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_T-CD8-positive,_alpha-beta_T_cell-T_CD8_c08-IL2RB|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.26e-05 | 193 | 78 | 5 | 54604c2c5dce2ff6f3ec7ca82b595b09b8cdafe8 | |
| ToppCell | 3'_v3-bone_marrow-Lymphocytic_NK|bone_marrow / Manually curated celltypes from each tissue | 2.26e-05 | 193 | 78 | 5 | e790ab76c12f74a13936c231076f1e397283efb3 | |
| ToppCell | renal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Intermediate_tubule_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group | 2.32e-05 | 194 | 78 | 5 | e577d9e88390b36b5a09b97fe1026089892275a3 | |
| ToppCell | mild-Myeloid-Neutrophils_1|mild / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 2.32e-05 | 194 | 78 | 5 | ccd911ce3251cd1c60f1fb2ce00650fbe7a379bb | |
| ToppCell | 3'_v3-bone_marrow-Lymphocytic_NK-NK_CD16|bone_marrow / Manually curated celltypes from each tissue | 2.32e-05 | 194 | 78 | 5 | 7773501e076d470158dbc1d7f10c67152b326eb7 | |
| ToppCell | T_cells-CD56_dim_CD16+_NK_cells|World / Immune cells in Kidney/Urine in Lupus Nephritis | 2.32e-05 | 194 | 78 | 5 | 335c6c2f3f319d4f19eace62f8826a0f40c130f6 | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_ILC-NK_cell|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.43e-05 | 196 | 78 | 5 | 78b28b263deaa43590b38597186222c6447ad25f | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_ILC|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.43e-05 | 196 | 78 | 5 | 3e78e307c9c991c1aadc85c61d401431cf75eaec | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_convalescent_d36-51-Lymphocytic-Lymphocytic_ILC-NK_cell-NK_c01-FCGR3A|Mild-Moderate_convalescent_d36-51 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.43e-05 | 196 | 78 | 5 | f0566f2ef96584ed6d9247b149218376fb509915 | |
| ToppCell | Mild/Remission-Plasmablast|Mild/Remission / disease group and sub_cluster of B and Plasma cells(res = 0.5) | 2.43e-05 | 196 | 78 | 5 | dcf0a804a79a05454658498d1f87320c7e079219 | |
| ToppCell | 3'-GW_trimst-2-SmallIntestine-Hematopoietic-Myeloid|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.49e-05 | 197 | 78 | 5 | 09a2c0c0f9c2442743414236c2d5c1f27be66e4c | |
| ToppCell | severe-Lymphocytic-NK_cells|Lymphocytic / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 2.55e-05 | 198 | 78 | 5 | 6ef22f33b43e9adceea11738e3cba0e8b59b4ec6 | |
| ToppCell | Control-Control-Lymphocyte-T/NK-NK_activated|Control / Disease, condition lineage and cell class | 2.55e-05 | 198 | 78 | 5 | 76d5fe4e5bbe6c73a6ca409b80b5c3924e07cab7 | |
| ToppCell | mild_COVID-19_(asymptomatic)-NK|World / disease group, cell group and cell class (v2) | 2.55e-05 | 198 | 78 | 5 | 7a0aac52d785037455e068e1b25de4b2bf0fff79 | |
| ToppCell | mild-Lymphocytic-NK_cells|Lymphocytic / Cohort 2 (Rhapsody WB + PBMC) with disease condition, lineage and cell classs | 2.55e-05 | 198 | 78 | 5 | 1d20fc9948965de52a98f758035edfdd12cafc5f | |
| ToppCell | mild_COVID-19_(asymptomatic)-NK|mild_COVID-19_(asymptomatic) / disease group, cell group and cell class (v2) | 2.55e-05 | 198 | 78 | 5 | 1e43181c13e054570046c7a973ddc1c586e259b0 | |
| ToppCell | wk_20-22-Hematologic-Myeloid|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 2.61e-05 | 199 | 78 | 5 | 0740166c51ce63edf83c4b98fce057f1440116d7 | |
| ToppCell | wk_20-22-Hematologic|wk_20-22 / Celltypes from embryonic and fetal-stage human lung | 2.61e-05 | 199 | 78 | 5 | f360c75e169536578550bed79461a5947e2472b1 | |
| ToppCell | Control-Control-Myeloid-Neutrophil|Control / Disease, condition lineage and cell class | 2.68e-05 | 200 | 78 | 5 | 95c41f147a1594d49e73cb56d86d301c3115ce20 | |
| ToppCell | Parenchymal-10x5prime-Immune_Lymphocytic-NK-ILC-T_NK-NK|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 2.68e-05 | 200 | 78 | 5 | 0a6fc7eff94e2f71af9f31a01779aafd2f4a6699 | |
| ToppCell | Parenchymal-10x5prime-Immune_Lymphocytic-NK-ILC-T_NK-NK_CD11d|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations | 2.68e-05 | 200 | 78 | 5 | eda7a1d822e8663510662bc0ca34eaccc88d71ca | |
| ToppCell | LPS_IL1RA-Mesenchymal_myocytic|LPS_IL1RA / Treatment groups by lineage, cell group, cell type | 2.68e-05 | 200 | 78 | 5 | 77631c471cc5d453a749784f838cfa6408caf09b | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Myeloid-neutrophil|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.79e-05 | 133 | 78 | 4 | f6e9a1301a3379847b215303a9b0c028841e2cc0 | |
| ToppCell | droplet-Lung-immune-endo-depleted-3m-Myeloid-Neutrophil|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 8.79e-05 | 133 | 78 | 4 | 292ecfcadbaf15e0d34a3ab9bf511ab1065888bd | |
| ToppCell | facs-Marrow-B-cells-3m-Myeloid-granulocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.85e-05 | 137 | 78 | 4 | 4dcb15de821439011df1bb0bbd7682d674bd725d | |
| ToppCell | facs-Marrow-B-cells-3m-Myeloid-granulocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 9.85e-05 | 137 | 78 | 4 | c05ceeb7b483324604cb3f647d2da2b3786071b1 | |
| ToppCell | facs-Lung-Endomucin-24m-Endothelial-Capillary_Type_1_Cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.23e-04 | 145 | 78 | 4 | 96712c68ab759d7ade0d912581a1a7c25dc6def8 | |
| ToppCell | frontal_cortex-Non-neuronal-macrophage-Macrophage-PVM_Mrc1|frontal_cortex / Per Region, Lineage, Cell class, Cell type, Cell subtype | 1.33e-04 | 148 | 78 | 4 | d3ea907f8f408e9bb97ed223a3089e403e35f911 | |
| ToppCell | PND03-Immune-Immune_Myeloid-Granulocytic-Mast|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.43e-04 | 151 | 78 | 4 | 9702575e47ececcf0a9f0f20a4a920dbb1ba5657 | |
| ToppCell | saliva-Mild-Moderate_progression_d12-25-Myeloid-Granulocytic-Neutrophil-Neu_c2-CXCR4(low)|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.43e-04 | 151 | 78 | 4 | b698ddc74565d47892c09c3f16d78038da2dd5e7 | |
| ToppCell | PND03-Immune-Immune_Myeloid-Granulocytic-Mast-Mast_mature|PND03 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif | 1.43e-04 | 151 | 78 | 4 | 673e4ab117b723c14d1df3804bbedc9e48284a9d | |
| ToppCell | saliva-Mild-Moderate_progression_d12-25-Myeloid-Granulocytic-Neutrophil-Neu_c6-FGF23|Mild-Moderate_progression_d12-25 / Compartment, severity and other cell annotations on 10x 3' data (130k) | 1.47e-04 | 152 | 78 | 4 | 0652ee3443e6fbb679d2c4f326239ae7c803f924 | |
| ToppCell | TCGA-Bone_and_Soft_Tissue-Solid_Tissue_Normal|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9 | 1.55e-04 | 154 | 78 | 4 | 89a60a79d07466d7ad05888d10a72d3b1ab384af | |
| ToppCell | TCGA-Bone_and_Soft_Tissue-Solid_Tissue_Normal-Connective_tissue_normal|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9 | 1.55e-04 | 154 | 78 | 4 | f1fea1a87e977221fa125b62287368be9af4987d | |
| ToppCell | TCGA-Bone_and_Soft_Tissue-Solid_Tissue_Normal-Connective_tissue_normal-Connective_tissue_normal|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9 | 1.55e-04 | 154 | 78 | 4 | b5604c0b0b9b283352a3f612f40883b9123475d1 | |
| ToppCell | TCGA-Bone_and_Soft_Tissue-Solid_Tissue_Normal-Connective_tissue_normal-Connective_tissue_normal-1|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9 | 1.55e-04 | 154 | 78 | 4 | 160b170a3ade8b246843c9854af332475c047ba0 | |
| ToppCell | facs-Spleen-nan-24m-Myeloid|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.62e-04 | 156 | 78 | 4 | 034d4359359a44c205c6931f38a375271ac2752b | |
| ToppCell | facs-Spleen-nan-24m-Myeloid-nan|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.62e-04 | 156 | 78 | 4 | 2a4dac4100c0339aad4905b8eaca6e8fe806718b | |
| ToppCell | facs-Spleen-nan-24m-Myeloid-granulocyte|Spleen / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.62e-04 | 156 | 78 | 4 | 21267718d3a3dc19988663b6846aed8bb3eae836 | |
| ToppCell | facs-Liver-Liver_non-hepato/SCs_st-18m-Myeloid-myeloid_leukocyte|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.75e-04 | 159 | 78 | 4 | cdbccb83af6220bab300dfe56443ff69f6e2043a | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic-precursor_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.79e-04 | 160 | 78 | 4 | c381ec6be8cf887861cc18f831a20db42f953fe1 | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic-pre_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 1.79e-04 | 160 | 78 | 4 | 25c8f3d2a6d14ff0ca0b965fce89d3ff22f40585 | |
| ToppCell | Smart-start-Cell-Wel_seq-Non-neoplastic-Myeloid-Mono-Mono_naive-A|Smart-start-Cell-Wel_seq / Platform, Oncotype, Lineage, Cell_class, celltype (level4), mutation group | 2.11e-04 | 167 | 78 | 4 | 1cd9e2af85c6c5b9e1d88991c87ac6980b387243 | |
| ToppCell | 5'-Parenchyma_lung-Immune_Myeloid-Dendritic-plasmacytoid_dendritic_cell-Plasmacytoid_DCs-Plasmacytoid_DCs_L.1.5.1.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5 | 2.26e-04 | 170 | 78 | 4 | b49f7c8a27078de2137ed04f74cfee30729cfa5e | |
| ToppCell | metastatic_Brain-B_lymphocytes-Plasma_cells|metastatic_Brain / Location, Cell class and cell subclass | 2.26e-04 | 170 | 78 | 4 | 53634da9e9c72f6400639954c286c6e38ea5a188 | |
| ToppCell | saliva-Severe-critical_progression_d12-22_no-steroids-Myeloid-Granulocytic-Neutrophil-Neu_c5-GSTP1(high)OASL(low)|Severe-critical_progression_d12-22_no-steroids / Compartment, severity and other cell annotations on 10x 3' data (130k) | 2.26e-04 | 170 | 78 | 4 | 07b561cd9c528bc8444c9385e1de621eee7b697e | |
| ToppCell | facs-Marrow-Granulocytes-3m-Myeloid-granulocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.31e-04 | 171 | 78 | 4 | ab21f20ec041cbaacccbd7da4dccdb77ec8bc5c6 | |
| ToppCell | facs-Marrow-Granulocytes-3m-Myeloid-granulocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.31e-04 | 171 | 78 | 4 | 97ad2cfff568a9d006ab1d2e6e00946ee4e3beb3 | |
| ToppCell | NS-critical-LOC-Lymphoid-NK|LOC / Location, Severity, dps_group, Lineage and Cell class of Upper airway (combined) | 2.31e-04 | 171 | 78 | 4 | adda76991d9b150bb8ccf3989b7cbbf41843cf0b | |
| ToppCell | droplet-Marrow-BM-1m-Myeloid-granulocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.31e-04 | 171 | 78 | 4 | 8a0c08f0aa3a80cd6346c81deb242e430ebd897b | |
| ToppCell | droplet-Marrow-nan-3m-Myeloid-granulocyte|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.36e-04 | 172 | 78 | 4 | d354424c1f861b6607dfd63b9724f4c237b30275 | |
| ToppCell | Plasma_cells|World / lung cells shred on cell class, cell subclass, sample id | 2.41e-04 | 173 | 78 | 4 | 52a387e2a4694af61a9223a4c2ecf4e6f762c064 | |
| ToppCell | 10x5'-GI_small-bowel-Mast|GI_small-bowel / Manually curated celltypes from each tissue | 2.47e-04 | 174 | 78 | 4 | e94c980b25edfd0e8598c416828801fcc00e8ead | |
| ToppCell | 10x5'-GI_small-bowel-Mast-Mast_cells|GI_small-bowel / Manually curated celltypes from each tissue | 2.47e-04 | 174 | 78 | 4 | 05525bf0a2bde2be4f7c147b17a24530ce8819e0 | |
| ToppCell | TCGA-Bone_and_Soft_Tissue-Primary_Tumor-Sarcoma-Dedifferentiated_Liposarcoma|TCGA-Bone_and_Soft_Tissue / Sample_Type by Project: Shred V9 | 2.52e-04 | 175 | 78 | 4 | 2eca4c168dea2017ea0e383006e28abed22f32ec | |
| ToppCell | facs-Marrow-B-cells-24m-Lymphocytic|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.58e-04 | 176 | 78 | 4 | c6484334187f64cd00cd35e77d8ae436556b4260 | |
| ToppCell | facs-Marrow-Granulocytes-3m-Myeloid|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.63e-04 | 177 | 78 | 4 | 065bebd22031f143e90a407f952b444a3f8818c7 | |
| ToppCell | facs-Marrow-Granulocytes-3m|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.63e-04 | 177 | 78 | 4 | eb304f20aab075bd17aa3aef819386c0e1a235bd | |
| ToppCell | LPS-antiTNF-Myeloid-Neutrophils-Neutrophils|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.69e-04 | 178 | 78 | 4 | afcc92e8fe313c85eaf617cf4dbc3058da6c99d6 | |
| ToppCell | LPS-antiTNF-Myeloid-Neutrophils|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.69e-04 | 178 | 78 | 4 | bd689205bc92cda5f71df64c2332ff76adcd84b4 | |
| ToppCell | 3'-GW_trimst-2-LargeIntestine-Hematopoietic-Myeloid-Macrophages|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.75e-04 | 179 | 78 | 4 | 409364d916c5e7e2291284cc74351d8f8a8447ac | |
| ToppCell | 3'-GW_trimst-2-SmallIntestine-Mesenchymal-mesothelial_cell|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.75e-04 | 179 | 78 | 4 | 056df2aaff750e0e283e7da78fcc3c90c366aac0 | |
| ToppCell | LPS_only-Myeloid-Neutrophils|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.75e-04 | 179 | 78 | 4 | d0a03e498afcfeb657037889685ecd77bed07e6c | |
| ToppCell | 3'-GW_trimst-2-SmallIntestine-Mesenchymal-mesothelial_cell-Mesothelium|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.75e-04 | 179 | 78 | 4 | f5f3945ef3b9efc5921a71fd51deeb2c80f0ce11 | |
| ToppCell | 3'_v3-GI_small-bowel-Lymphocytic_NK|GI_small-bowel / Manually curated celltypes from each tissue | 2.75e-04 | 179 | 78 | 4 | 535bdfdd990ba9ee3edc8f3ad15297f8fb5a266e | |
| ToppCell | LPS_only-Myeloid-Neutrophils-Neutrophils|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2 | 2.75e-04 | 179 | 78 | 4 | d034651a5a355a58f5e15db627869f4feebdfe35 | |
| ToppCell | COVID-19-kidney-tDL|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.81e-04 | 180 | 78 | 4 | 864c895b5eaedefae86f5829fa344f7b686fb59f | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_B-Plasma_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.87e-04 | 181 | 78 | 4 | 6cdee2f56bc633b387b4dbbd78c624edbd712c24 | |
| ToppCell | renal_medulla_nuclei-Hypertensive_with+without-CKD-Immune-Lymphocytic_B-Plasma_Cell-|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group | 2.87e-04 | 181 | 78 | 4 | b75b8b025257bccfe661fd0f92ab284b2a9c12ee | |
| ToppCell | TCGA-Skin-Metastatic-Melanoma-Skin_Cutaneous_Melanoma-2|TCGA-Skin / Sample_Type by Project: Shred V9 | 2.87e-04 | 181 | 78 | 4 | 9d5b331cabc5524f0a9fd8b571e87be4c447c7d4 | |
| ToppCell | COVID-19-kidney-Stressed_PCT|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.87e-04 | 181 | 78 | 4 | 6980ea624151da32b7f537f263e40fcb87a02e81 | |
| ToppCell | cellseq2-Immune-Hematopoietic-Granulocytic-Neutrophil|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.93e-04 | 182 | 78 | 4 | 1932d77491d6d46278f01fd70eb469ef1b356619 | |
| ToppCell | facs-Kidney-nan-3m|Kidney / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation | 2.93e-04 | 182 | 78 | 4 | 4c5d14e33ebdf117b5aa9e2f57aaa89aa51f72bf | |
| ToppCell | COVID-19-kidney-Distal_Epi_Doublet_(PCT)|COVID-19 / Disease (COVID-19 only), tissue and cell type | 2.93e-04 | 182 | 78 | 4 | 9d67717a6e13bcb54c1297a3e4e3abf4e51628a3 | |
| ToppCell | cellseq2-Immune-Hematopoietic-Granulocytic|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.99e-04 | 183 | 78 | 4 | cfbf8539104cef9ca830ad4f6bb278746f7078f7 | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B-B_plasma-female|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.99e-04 | 183 | 78 | 4 | dd15e1463a0d57d14800de0df0645c81c56926ae | |
| ToppCell | systemic_lupus_erythematosus-treated-Lymphocytic_B-B_plasma|systemic_lupus_erythematosus / PBMC cell types (v2) per disease, treatment status, and sex | 2.99e-04 | 183 | 78 | 4 | 8ace19c38b89556d2504258a63aa5a2b14f5cd36 | |
| ToppCell | 5'-GW_trimst-2-SmallIntestine-Hematopoietic-Myeloid-MPO+_mono-neutrophil|GW_trimst-2 / Celltypes from developing, pediatric, Crohn's, & adult GI tract | 2.99e-04 | 183 | 78 | 4 | 01c7f01498a9894920edf8243e41187cbdf90688 | |
| ToppCell | cellseq2-Immune-Hematopoietic|cellseq2 / Celltype signatures by Technology, Lineage, Lineage_subclass, Celltype_group, Cell_type2 | 2.99e-04 | 183 | 78 | 4 | 324ec4374b552da7ce03809945b3a0798342d4ba | |
| ToppCell | PBMC_fresh-frozen-Mild-Moderate_progression_d02_child-Lymphocytic-Lymphocytic_B-Plasma_cell-B_c05-MZB1-XBP1|Mild-Moderate_progression_d02_child / Compartment, severity and other cell annotations on 10x 3' data (130k) | 3.05e-04 | 184 | 78 | 4 | af6522586d012e91241f3e06c60f9d1881e95646 | |
| Drug | Lanicemine | 3.90e-12 | 14 | 78 | 6 | CID003038485 | |
| Drug | Yfrkd | 8.65e-12 | 7 | 78 | 5 | CID000129984 | |
| Drug | 1hiv | 2.30e-11 | 8 | 78 | 5 | CID005479205 | |
| Drug | Chebi:36708 | 2.30e-11 | 8 | 78 | 5 | CID011966289 | |
| Drug | pipobroman | 1.03e-10 | 10 | 78 | 5 | CID000004842 | |
| Drug | Murabutida | 1.23e-10 | 43 | 78 | 7 | CID005362018 | |
| Drug | flesinoxan | 1.88e-10 | 11 | 78 | 5 | CID000057347 | |
| Drug | R 842 | 5.22e-10 | 13 | 78 | 5 | CID000130714 | |
| Drug | AC1O52EF | 5.22e-10 | 13 | 78 | 5 | CID006450817 | |
| Drug | NM 108 | 5.93e-10 | 29 | 78 | 6 | CID000500901 | |
| Drug | gunacin | 8.10e-10 | 14 | 78 | 5 | CID000198547 | |
| Drug | 2-hydroxyisovaleric acid | 8.52e-10 | 56 | 78 | 7 | CID000099823 | |
| Drug | pppA2'-5'A2'-5'A | 1.21e-09 | 15 | 78 | 5 | CID000125229 | |
| Drug | MCNU | 2.39e-09 | 36 | 78 | 6 | CID000071741 | |
| Drug | YNK01 | 2.48e-09 | 17 | 78 | 5 | CID000084071 | |
| Drug | FMAU | 2.84e-09 | 37 | 78 | 6 | CID000072327 | |
| Drug | anagrelide | 3.36e-09 | 38 | 78 | 6 | CID000002182 | |
| Drug | p203 | 3.43e-09 | 18 | 78 | 5 | CID000019228 | |
| Drug | podophyllin | 3.43e-09 | 18 | 78 | 5 | CID011979494 | |
| Drug | Nyco | 3.43e-09 | 18 | 78 | 5 | CID000071618 | |
| Drug | Ciluprevir [USAN] | 6.17e-09 | 20 | 78 | 5 | CID006450803 | |
| Drug | val-mCyd | 6.17e-09 | 20 | 78 | 5 | CID006918726 | |
| Drug | L DO | 8.08e-09 | 21 | 78 | 5 | CID000097725 | |
| Drug | 2-chloro-3'-deoxyadenosine | 8.46e-09 | 44 | 78 | 6 | CID003034808 | |
| Drug | formosanin C | 1.04e-08 | 22 | 78 | 5 | CID000073597 | |
| Drug | Hiltonol | 1.33e-08 | 23 | 78 | 5 | CID000431963 | |
| Drug | AC1L1ZCT | 1.67e-08 | 24 | 78 | 5 | CID000038235 | |
| Drug | cycloferon | 1.67e-08 | 24 | 78 | 5 | CID000038072 | |
| Drug | hycanthone | 2.09e-08 | 25 | 78 | 5 | CID000003634 | |
| Drug | LB80380 | 2.09e-08 | 25 | 78 | 5 | CID006480442 | |
| Drug | bropirimine | 2.39e-08 | 52 | 78 | 6 | CID000065457 | |
| Drug | ABMP | 2.58e-08 | 26 | 78 | 5 | CID000080567 | |
| Drug | inosiplex | 3.15e-08 | 27 | 78 | 5 | CID000037510 | |
| Drug | VX-497 | 3.15e-08 | 27 | 78 | 5 | CID000153241 | |
| Drug | Beryllium | 3.77e-08 | 56 | 78 | 6 | CID000107649 | |
| Drug | AC1NRD2B | 3.83e-08 | 28 | 78 | 5 | CID005289317 | |
| Drug | NSC141633 | 4.61e-08 | 29 | 78 | 5 | CID000003628 | |
| Drug | Lps2 | 4.67e-08 | 58 | 78 | 6 | CID000454710 | |
| Drug | penciclovir | 5.52e-08 | 30 | 78 | 5 | CID000004725 | |
| Drug | DZNep | 5.52e-08 | 30 | 78 | 5 | CID000073087 | |
| Drug | poly rI:rC | 5.52e-08 | 30 | 78 | 5 | CID011979660 | |
| Drug | CHEMBL466993 | 7.76e-08 | 32 | 78 | 5 | CID005320808 | |
| Drug | copolymer 1 | 1.03e-07 | 66 | 78 | 6 | CID003081884 | |
| Drug | carprofen | 1.07e-07 | 34 | 78 | 5 | CID000002581 | |
| Drug | oxymatrine | 1.07e-07 | 34 | 78 | 5 | CID000114850 | |
| Drug | tenofovir disoproxil fumarate | 1.07e-07 | 34 | 78 | 5 | CID005481350 | |
| Drug | Azitidin | 1.18e-07 | 169 | 78 | 8 | CID000005726 | |
| Drug | tilorone | 1.24e-07 | 35 | 78 | 5 | CID000005475 | |
| Drug | lobucavir | 1.24e-07 | 35 | 78 | 5 | CID000060786 | |
| Drug | A809128 | 1.44e-07 | 36 | 78 | 5 | CID003392279 | |
| Drug | barium iodide | 1.54e-07 | 4 | 78 | 3 | CID000083684 | |
| Drug | N6-methyl-(R)-roscovitine | 1.59e-07 | 71 | 78 | 6 | CID005289296 | |
| Drug | pyran | 1.66e-07 | 37 | 78 | 5 | CID000033703 | |
| Drug | fotemustine | 1.90e-07 | 38 | 78 | 5 | CID000104799 | |
| Drug | U-10149A | 2.17e-07 | 123 | 78 | 7 | CID000003928 | |
| Drug | isofagomine lactam | 2.18e-07 | 39 | 78 | 5 | CID000448980 | |
| Drug | dideoxyinosine | 2.22e-07 | 75 | 78 | 6 | CID000003043 | |
| Drug | 1 Jak | 2.40e-07 | 76 | 78 | 6 | CID000446429 | |
| Drug | 2',3'-dideoxycytidine (ddC | 2.40e-07 | 76 | 78 | 6 | CID000005718 | |
| Drug | 1 ind | 3.19e-07 | 42 | 78 | 5 | CID003037877 | |
| Drug | imiquimod | 3.52e-07 | 132 | 78 | 7 | CID000057469 | |
| Drug | AC1NRBRB | 3.60e-07 | 43 | 78 | 5 | CID005288597 | |
| Drug | NSC 312887 | 3.60e-07 | 43 | 78 | 5 | CID000003368 | |
| Drug | Sesquimustard | 3.60e-07 | 43 | 78 | 5 | CID000019092 | |
| Drug | neopterine | 3.70e-07 | 133 | 78 | 7 | CID000004455 | |
| Drug | B132 | 3.85e-07 | 5 | 78 | 3 | CID002734031 | |
| Drug | Solvent Yellow-?14 | 5.09e-07 | 46 | 78 | 5 | CID005354458 | |
| Drug | AC1L9AL3 | 5.09e-07 | 46 | 78 | 5 | CID000441122 | |
| Drug | 2'-deoxy-3'-thiacytidine | 5.39e-07 | 87 | 78 | 6 | CID000003877 | |
| Drug | entecavir | 5.68e-07 | 47 | 78 | 5 | CID000153941 | |
| Drug | NSC289637 | 6.32e-07 | 48 | 78 | 5 | CID000004213 | |
| Drug | D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH2 | 7.02e-07 | 49 | 78 | 5 | CID000365716 | |
| Drug | adefovir dipivoxil | 7.02e-07 | 49 | 78 | 5 | CID000060871 | |
| Drug | HCV-371 | 7.68e-07 | 6 | 78 | 3 | CID003013096 | |
| Drug | TISCH | 8.60e-07 | 51 | 78 | 5 | CID000125486 | |
| Drug | trifluorothymidine | 8.60e-07 | 51 | 78 | 5 | CID000006256 | |
| Drug | amantadine | 9.07e-07 | 95 | 78 | 6 | CID000002130 | |
| Drug | famciclovir | 9.49e-07 | 52 | 78 | 5 | CID000003324 | |
| Drug | busulfan | 1.03e-06 | 97 | 78 | 6 | CID000002478 | |
| Drug | Ampligen | 1.05e-06 | 53 | 78 | 5 | CID000038077 | |
| Drug | 2-fluoroadenine arabinoside | 1.19e-06 | 158 | 78 | 7 | CID000003367 | |
| Drug | m IU | 1.38e-06 | 56 | 78 | 5 | CID006852123 | |
| Drug | HMPV | 1.53e-06 | 25 | 78 | 4 | CID004444603 | |
| Drug | rosuvastatin | 1.80e-06 | 59 | 78 | 5 | CID000446157 | |
| Drug | AC1L1U53 | 1.95e-06 | 60 | 78 | 5 | CID000060907 | |
| Drug | sarcolysin | 2.09e-06 | 172 | 78 | 7 | CID000004053 | |
| Drug | AC1LAD6M | 2.14e-06 | 8 | 78 | 3 | CID000511663 | |
| Drug | O4-[3-[(1S)-6,7-dimethoxy-2-methyl-1-(3,4,5-trimethoxyphenyl)-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] O1-[3-[(1R)-6,7-dimethoxy-2-methyl-1-[(3,4,5-trimethoxyphenyl)methyl]-3,4-dihydro-1H-isoquinolin-2-ium-2-yl]propyl] (Z)-2-chlorobut-2-enedioate | 2.14e-06 | 8 | 78 | 3 | CID010011375 | |
| Drug | NSC105014 | 2.15e-06 | 110 | 78 | 6 | CID000001546 | |
| Drug | bexarotene | 2.26e-06 | 111 | 78 | 6 | CID000082146 | |
| Drug | NSC-218321 | 2.64e-06 | 114 | 78 | 6 | CID000004739 | |
| Drug | AC1L1HZP | 2.70e-06 | 64 | 78 | 5 | CID000004361 | |
| Drug | adefovir | 2.70e-06 | 64 | 78 | 5 | CID000060172 | |
| Drug | resiquimod | 2.78e-06 | 115 | 78 | 6 | CID000159603 | |
| Drug | 1k1n | 3.04e-06 | 182 | 78 | 7 | CID000177837 | |
| Drug | AC1O51IP | 3.15e-06 | 66 | 78 | 5 | CID006450363 | |
| Drug | Telaprevir | 3.20e-06 | 9 | 78 | 3 | CID003010818 | |
| Drug | boceprevir | 3.20e-06 | 9 | 78 | 3 | CID010324367 | |
| Drug | azathioprine | 3.56e-06 | 120 | 78 | 6 | CID000002265 | |
| Drug | 9-cis-retinol | 3.65e-06 | 357 | 78 | 9 | CID000001071 | |
| Disease | triacylglycerol 58:6 measurement | 1.72e-04 | 8 | 74 | 2 | EFO_0010440 | |
| Disease | serum gamma-glutamyl transferase measurement | 4.60e-04 | 914 | 74 | 9 | EFO_0004532 | |
| Disease | type 2 diabetes mellitus (biomarker_via_orthology) | 5.19e-04 | 147 | 74 | 4 | DOID:9352 (biomarker_via_orthology) | |
| Disease | protein C measurement | 8.24e-04 | 17 | 74 | 2 | EFO_0004633 | |
| Disease | Antibody Deficiency Syndrome | 8.24e-04 | 17 | 74 | 2 | C0003257 | |
| Disease | dermatomyositis (is_marker_for) | 8.24e-04 | 17 | 74 | 2 | DOID:10223 (is_marker_for) | |
| Disease | trauma exposure measurement | 9.34e-04 | 172 | 74 | 4 | EFO_0010703 | |
| Disease | atherosclerosis (biomarker_via_orthology) | 1.14e-03 | 20 | 74 | 2 | DOID:1936 (biomarker_via_orthology) | |
| Disease | liver cirrhosis (is_marker_for) | 1.16e-03 | 82 | 74 | 3 | DOID:5082 (is_marker_for) | |
| Disease | progression free survival, ovarian serous carcinoma | 1.39e-03 | 22 | 74 | 2 | EFO_0004920, EFO_1001516 | |
| Disease | Immunologic Deficiency Syndromes | 1.52e-03 | 23 | 74 | 2 | C0021051 | |
| Disease | glioblastoma (is_implicated_in) | 1.65e-03 | 24 | 74 | 2 | DOID:3068 (is_implicated_in) | |
| Disease | diffusing capacity of the lung for carbon monoxide | 1.83e-03 | 96 | 74 | 3 | EFO_0009369 | |
| Disease | sensory perception of bitter taste | 1.94e-03 | 26 | 74 | 2 | GO_0050913 | |
| Disease | 3-methoxytyrosine measurement | 2.09e-03 | 27 | 74 | 2 | EFO_0021009 | |
| Disease | response to paliperidone, schizophrenia symptom severity measurement | 2.15e-03 | 216 | 74 | 4 | EFO_0007925, EFO_0007927 | |
| Disease | Pigmented Basal Cell Carcinoma | 2.25e-03 | 28 | 74 | 2 | C1368275 | |
| Disease | Carcinoma, Basal Cell | 2.41e-03 | 29 | 74 | 2 | C4721806 | |
| Disease | xanthurenate measurement | 2.41e-03 | 29 | 74 | 2 | EFO_0010551 | |
| Disease | 1,5 anhydroglucitol measurement | 2.41e-03 | 29 | 74 | 2 | EFO_0008009 |
| Peptide | Gene | Start | Entry |
|---|---|---|---|
| NSTFNGISQEVIQHM | 1001 | Q68DN1 | |
| FTHQMVQFLSTLEQN | 2216 | Q9HCE0 | |
| ALQHMTDFAIQFNKN | 746 | P63010 | |
| KQQFLNMTTFDHQNS | 476 | Q9Y2D8 | |
| NMTTFDHQNSENVKL | 481 | Q9Y2D8 | |
| FRHVQNNLMRNSTTE | 331 | Q9H9E3 | |
| HLNFTNNMGEQVTFD | 466 | P41180 | |
| TLSTQLFQMVHTQRQ | 181 | P53367 | |
| TLQDEFGQMSFDHQQ | 366 | Q86XR8 | |
| NFINLILNHMQSETS | 2236 | Q86UQ4 | |
| DTHLFETNQMTQQGT | 156 | Q5JTZ5 | |
| LAHQFTQVQRDMFTL | 131 | P28907 | |
| EAHQQFARNVLFQTM | 296 | Q7Z5Q5 | |
| QNFSKLLNDNIFHMS | 471 | P06400 | |
| FVLSFLSQMNVVNHF | 216 | P20936 | |
| TQFSLMQFSNKFQTH | 186 | P20702 | |
| IAFFQDSLINQMTQV | 101 | Q96PE3 | |
| HENSFFINEALVQMS | 1561 | Q8N1W1 | |
| NITVFRQTSTHLQMA | 486 | Q6W4X9 | |
| HEMIQQTFNLFSTED | 81 | P01566 | |
| HFCNFTTIAQNVIMN | 46 | O00476 | |
| INILQSFHNVQQMAI | 276 | Q9NZR2 | |
| MNATTIHFNLTFQNT | 606 | Q3T906 | |
| IQIAFSQHSNFMDLV | 1266 | O75882 | |
| SQHSNFMDLVQFFVT | 1271 | O75882 | |
| QNTMQSHIIFNNYIT | 2671 | O43451 | |
| HEMIQQTFNLFSTKD | 81 | P01568 | |
| TNEKLQQFFNQHMFV | 526 | A7E2Y1 | |
| QTSLSMVNHRLQSFF | 761 | P26006 | |
| TQHLAMTFNQVIQTG | 581 | O95373 | |
| LQFGNQTLHVSTVQM | 1456 | Q14999 | |
| HEMIQQTFNLFSTKD | 81 | P01569 | |
| LHQLQNFNTLMAVTG | 281 | Q8TDF6 | |
| HEMIQQTFNLFSTED | 81 | P01567 | |
| ESQNLSMFLANHNRI | 206 | Q96F07 | |
| TFLVMSNAINIHQTA | 1321 | Q7Z442 | |
| MQNFTLHEVTNDFDN | 1036 | Q9UMZ3 | |
| SRNMHQENQTTITEF | 11 | Q8NGQ3 | |
| SFSEFIKQMQQQEHD | 221 | Q5VTY9 | |
| QINEQMLFHGTSSEF | 196 | Q9NR21 | |
| EFEQIQSQTFSQVQM | 541 | Q9P2D7 | |
| THQKMTDFEQLNQFD | 61 | Q3L8U1 | |
| QFRTHPSFQDIMQNI | 566 | Q7RTS9 | |
| QTQTTKFHQDQDTIM | 296 | Q4L180 | |
| SHIYQNQFVQMILNS | 146 | P16671 | |
| MNHLTLEQTFFSQVL | 6 | Q9NSG2 | |
| FSFHSCLQLAEQMTQ | 216 | Q9NSG2 | |
| FSQHNTIMDLVQFFV | 1221 | Q5VV63 | |
| SQLLHTQMFSQFIEE | 621 | O75064 | |
| KQFLSEENMATHFSQ | 56 | Q9NWW0 | |
| HEMIQQTFNLFSTKD | 81 | P32881 | |
| TNHMVFQFDCTNTLN | 656 | Q9Y678 | |
| QVQNLVFHSLTVTQM | 606 | Q6IA86 | |
| FEAILQFQMNHSVLQ | 241 | Q86SQ9 | |
| QKHTVEFNQLAMANS | 296 | Q9ULM6 | |
| HEMIQQTFNLFSTED | 81 | P01571 | |
| PHFTVTTVLFMNNNT | 166 | P59533 | |
| TQFLMAVFQATSQIQ | 4456 | Q8NF91 | |
| LASEQQHSAQAMFNL | 656 | Q9UBV2 | |
| AISAFHEMIQQTFNL | 76 | P05015 | |
| HEMIQQTFNLFSTKD | 81 | P05015 | |
| FQISLHFTVCLMNFN | 286 | P32249 | |
| VQQTTERHNQAFMAL | 2526 | Q9NT68 | |
| HEMIQQTFNLFSTED | 81 | P05014 | |
| TQAFFLLVNQHSMVS | 76 | Q9H492 | |
| TTNSYLMQHQESIIQ | 801 | Q8WYL5 | |
| SSVFSSRQLHQLEQM | 41 | Q8IZF4 | |
| SDTNQMNVHNLAIVF | 1096 | Q96P48 | |
| FVTMILFVANTQSNQ | 141 | Q8NCR9 | |
| QKHTVEFNQVAMANS | 296 | Q96LI5 | |
| LPQVSQQLQTMFHHF | 86 | Q969E8 | |
| TLAQNHSRINLMDFN | 221 | Q92911 | |
| VFQALQRLHMTIFSQ | 16 | Q86W42 | |
| FMLQQQLSNAQLHSL | 56 | P78364 | |
| LHVTNENMEVTNQQF | 196 | Q96NL6 | |
| ISHNFTQNPDMFNII | 2926 | Q86WI1 | |
| IMVQATTLNVAFNSH | 256 | Q6NXT6 | |
| NATQFNITDEIMSQF | 101 | O43294 | |
| QKFFFQTELQNHTMS | 1266 | Q2M1K9 | |
| DHMTFSQRVANFLVN | 201 | P19224 | |
| NVQDSNGNTLMHILF | 541 | O15050 | |
| SLQVLNMSHNNFFSL | 521 | O00206 | |
| QAHTQQNMVEKFSQL | 431 | O75113 | |
| LQQFFVQHVFTMEQE | 461 | Q6PIF6 |